Notch Signaling and Gamma-Secretase Modulators for Alzheimer's Disease

Overview

Overview

This page catalogs biotechnology and pharmaceutical companies developing therapeutics targeting the Notch signaling pathway and gamma-secretase for [Alzheimer's disease](/diseases/alzheimers-disease). The Notch pathway has emerged as a critical regulator of amyloid precursor protein (APP) processing and neurodegenerative processes through its roles in neural development, synaptic plasticity, and cellular stress responses["@lasky2020"]. In AD, Notch signaling intersects with key pathological processes including amyloid-beta production, tau phosphorylation, neuroinflammation, and synaptic dysfunction.

Gamma-secretase is a central enzyme in AD pathogenesis as it performs the final cleavage of APP to produce amyloid-beta peptides. While gamma-secretase inhibitors have shown preclinical promise, selective Notch modulation and gamma-secretase modulation represent promising alternative approaches that may preserve essential cellular functions while providing therapeutic benefit["@bittner2016"].

Scientific Background

Notch Signaling in Alzheimer's Disease

The Notch family consists of four receptors (Notch1-4) and multiple ligands (Jagged1, Jagged2, DLL1, DLL3, DLL4). In AD, Notch signaling plays several important roles[@wang2014]:

• APP processing: Notch and APP share common processing by gamma-secretase, creating competitive substrate relationships
• Synaptic plasticity: Notch regulates synaptic formation and function, processes compromised in AD
• Neuroinflammation: Notch-NF-κB cross-talk represents a key intersection between neuroinflammation and AD pathology
• Neuronal survival: Notch signaling influences neuronal viability and resistance to amyloid toxicity

Gamma-Secretase as a Therapeutic Target

Gamma-secretase is a proteolytic enzyme complex (comprising PSEN1/Presenilin-1, PSEN2/Presenilin-2, NCT/ Nicastrin, and APH-1a/b) that cleaves over 100 substrates including APP and Notch receptors[@schliebs2012]. While gamma-secretase inhibitors (GSIs) have shown preclinical promise for reducing amyloid-beta production, they face significant challenges:

• Pleiotropic functions: Gamma-secretase processes over 100 substrates beyond APP
• Side effects: Complete inhibition causes gastrointestinal toxicity and hematological effects
• Cognitive worsening: Some GSIs showed cognitive worsening in clinical trials

Gamma-Secretase Modulators (GSMs)

GSMs represent a distinct class of compounds that:

• Modulate (rather than inhibit) gamma-secretase activity
• Shift APP processing toward non-amyloidogenic pathways
• Preserve Notch signaling and other essential functions
• May provide a wider therapeutic window than GSIs

Companies and Programs

Large Pharmaceutical Companies

Yuhan Corporation

Status: Phase 1 Program: YH-4001 - Gamma-secretase modulator

Yuhan Corporation is developing YH-4001, a gamma-secretase modulator targeting APP processing in Alzheimer's disease. The modulator approach shifts processing away from amyloid-beta peptide production while preserving essential Notch signaling and other vital functions[@chen2019].

Mechanism: Modulation of gamma-secretase activity to reduce Aβ42/Aβ40 production while maintaining non-amyloidogenic processing.

Clinical Status: Phase 1 clinical trials in Alzheimer's disease.

See also: [Yuhan Corporation](/companies/yuhan-corporation) - for complete company profile

Merck & Co.

Status: Research Stage Program: MK-0752 and related Notch/gamma-secretase inhibitors

Merck has developed MK-0752, a potent gamma-secretase inhibitor that has been evaluated in clinical trials for oncology. Research has explored repurposing MK-0752 and related compounds for neurodegenerative diseases including AD.

Mechanism: Gamma-secretase inhibition reduces amyloid-beta production through complete enzyme inhibition.

Development Status: Research stage for AD; no active clinical trials in AD as of 2024.

Bristol-Myers Squibb

Status: Research Stage Program: Notch pathway modulators

Bristol-Myers Squibb has explored Notch signaling modulators in the context of cancer and inflammatory diseases. While not actively developing AD-specific programs, the company has contributed to understanding Notch biology that informs neurodegeneration research.

Relevant Research: BMS-906039 is a pan-Notch inhibitor investigated in oncology, used in research to understand Notch-APP interactions.

Biotechnology Companies

Vivoryon Therapeutics

Status: Phase 2b Program: Varoglutamstat (PQ912) - Glutaminyl Cyclase Inhibitor

While not directly a Notch/gamma-secretase modulator, varoglutamstat represents an innovative approach that works upstream of amyloid-beta by inhibiting glutaminyl cyclase, which catalyzes the formation of pyroglutamate-modified Aβ (pGlu-Aβ), a particularly toxic variant.

Mechanism: Inhibition of glutaminyl cyclase prevents formation of pGlu-Aβ, which acts as a seed for amyloid aggregation.

Clinical Status: Phase 2b VIVIAD trial in early AD.

See also: [Vivoryon Therapeutics](/companies/vivoryon) - for complete company profile

Denali Therapeutics

Status: Preclinical/Research Program: LRRK2 inhibitors with APP processing considerations

While Denali's primary focus is on LRRK2 inhibition for Parkinson's disease, their research program considers pathway interactions between LRRK2 and amyloid processing. Studies have shown that LRRK2 kinase activity can affect APP trafficking, providing potential opportunities for AD.

Development Status: Early-stage research exploring AD applications.

See also: [Denali Therapeutics](/companies/denali) - for complete company profile

Prothena Corporation

Status: Research Program: Protein clearance pathways

Prothena has developed expertise in protein clearance mechanisms relevant to neurodegenerative diseases. While their lead programs target alpha-synuclein (prasinezumab) and tau, their research platform encompasses autophagy and protein quality control pathways that intersect with Notch signaling.

Relevant Research: Understanding of how Notch modulates autophagy-lysosomal pathways may inform future AD combination approaches.

Academic and Research Programs

Multiple academic centers have conducted preclinical research on Notch/gamma-secretase modulators for AD:

| Institution | Focus | Status |
|-------------|-------|--------|
| Massachusetts General Hospital | Notch regulation of BACE1 | Preclinical |
| University of Cambridge | GSM mechanism studies | Research |
| Johns Hopkins University | Notch-Aβ interactions | Preclinical |
| University of Pennsylvania | iPSC models of Notch dysregulation | Research |

Pipeline Overview

| Company | Drug/Mechanism | Indication | Stage | Notes |
|---------|----------------|------------|-------|-------|
| Yuhan | YH-4001 (GSM) | AD | Phase 1 | Modulator approach |
| Merck | MK-0752 (GSI) | AD | Research | Repurposing potential |
| Vivoryon | Varoglutamstat (QCi) | AD | Phase 2b | pGlu-Aβ target |
| Denali | LRRK2 inhibitors | AD | Research | Pathway interactions |
| Prothena | Protein clearance | AD | Research | Autophagy modulators |

GSI = Gamma-Secretase Inhibitor GSM = Gamma-Secretase Modulator QCi = Glutaminyl Cyclase Inhibitor

Challenges in Developing Notch-Targeted AD Therapies

Pathway Complexity

The Notch pathway presents significant therapeutic challenges[@kelleher2015]:

• Pleiotropy: Notch has multiple functions throughout the body
• Compensation: Receptor redundancy may limit single-target approaches
• APP cross-talk: Notch and APP compete for gamma-secretase processing[@conti2015]

Safety Considerations

Complete Notch/gamma-secretase inhibition may cause[@bittner2016]:

• Gastrointestinal toxicity (notch inhibition affects gut epithelium)
• Hematological effects (impaired lymphocyte development)
• Cognitive worsening (observed in some GSI trials)

Therapeutic Windows

Optimal timing for Notch-targeted interventions:

• Pre-symptomatic: Prevent amyloid accumulation through neuroprotection
• Early disease: Modify disease progression
• Late disease: May have limited efficacy due to established pathology

Future Directions

Novel Therapeutic Approaches

Emerging strategies for Notch/gamma-secretase-targeted AD therapy:

• Notch-specific antibodies: Targeting specific Notch receptors with enhanced brain penetration
• Gamma-secretase modulators: Allosteric modulators with enhanced selectivity
• Combination therapy: GSM with anti-amyloid antibodies or other disease-modifying approaches
• Substrate-specific inhibitors: Targeting APP processing without affecting other substrates

Biomarker Development

Critical needs for clinical development:

• Soluble Notch receptors in cerebrospinal fluid
• Gamma-secretase activity assays
• APP metabolites as pathway activity markers
• Standardized assay protocols for clinical use

Personalized Medicine Approaches

Future directions include:

• Stratification based on gamma-secretase genotype variants
• Individualized timing of intervention based on biomarker profiles
• Combination of biomarker assessment with genetic profiling

Cross-References

• [Notch Signaling Pathway](/mechanisms/notch-signaling-pathway) - General mechanism
• [Notch Signaling in Neurodegeneration](/mechanisms/notch-signaling-neurodegeneration) - AD/PD mechanism
• [APP Processing Pathway](/mechanisms/app-processing) - Amyloid precursor protein processing
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade) - Disease mechanism
• [Gamma-Secretase Inhibitors for Parkinson's Disease](/companies/notch-gamma-secretase-parkinsons) - Related PD page
• [NOTCH1 Gene](/genes/notch1) - Gene page
• [PSEN1 Gene](/genes/psen1) - Presenilin-1 gene page
• [Alzheimer's Disease](/diseases/alzheimers-disease) - Disease overview

External Links

• [Nature Reviews Drug Discovery - Gamma-secretase challenges](https://www.nature.com/nrd)
• [PubMed - Notch signaling AD](https://pubmed.ncbi.nlm.nih.gov/?term=Notch+Alzheimer)
• [ClinicalTrials.gov - Gamma-secretase modulators](https://clinicaltrials.gov)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Notch Signaling and Gamma-Secretase Modulators for Alzheimer's Disease discovered through SciDEX knowledge graph analysis: